Genoway Financial Statements From 2010 to 2024

ALGEN Stock  EUR 3.93  0.09  2.34%   
Genoway financial statements provide useful quarterly and yearly information to potential Genoway investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Genoway financial statements helps investors assess Genoway's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Genoway's valuation are summarized below:
Genoway does not presently have any fundamental trends for analysis.
Check Genoway financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genoway's main balance sheet or income statement drivers, such as , as well as many indicators such as . Genoway financial statements analysis is a perfect complement when working with Genoway Valuation or Volatility modules.
  
This module can also supplement various Genoway Technical models . Check out the analysis of Genoway Correlation against competitors.

Genoway Company Current Valuation Analysis

Genoway's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Genoway Current Valuation

    
  35.89 M  
Most of Genoway's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genoway is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Genoway has a Current Valuation of 35.89 M. This is 99.75% lower than that of the Biotechnology sector and 99.23% lower than that of the Health Care industry. The current valuation for all France stocks is 99.78% higher than that of the company.

Genoway Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Genoway's current stock value. Our valuation model uses many indicators to compare Genoway value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genoway competition to find correlations between indicators driving Genoway's intrinsic value. More Info.
Genoway is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about  0.05  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genoway is roughly  20.00 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genoway's earnings, one of the primary drivers of an investment's value.

About Genoway Financial Statements

Genoway shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Genoway investors may analyze each financial statement separately, they are all interrelated. The changes in Genoway's assets and liabilities, for example, are also reflected in the revenues and expenses on on Genoway's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company was founded in 1999 and is based in Lyon, France. GENOWAY operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 105 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Genoway Stock Analysis

When running Genoway's price analysis, check to measure Genoway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genoway is operating at the current time. Most of Genoway's value examination focuses on studying past and present price action to predict the probability of Genoway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genoway's price. Additionally, you may evaluate how the addition of Genoway to your portfolios can decrease your overall portfolio volatility.